
Opinion|Videos|January 5, 2026
Real-World Tolerability and Safety Results for Axatilimab in cGVHD
Author(s)Leyla O. Shune, MD
Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.
Advertisement
Episodes in this series

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting. She compares the real-world results with the safety and tolerability outcomes observed in the AGAVE-201 (NCT04710576) trial, which supported the FDA approval of axatilimab for cGVHD.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
Why Awareness of Alcohol's Breast Cancer Risk Still Lags Decades Behind Tobacco
5



























